Industry leaders form alliance for microphysiological systems
European MPS companies including InSphero and Alveolix launched the Industry Alliance for Microphysiological Systems (IAMPS) to represent organoids and organs-on-chips providers, accelerate regulatory acceptance, standardize devices, create data-sharing platforms with pharma and CROs, secure biobanking resources, and influence Horizon Europe funding; IAMPS plans to engage EMA, FDA and other agencies and become operational in Q2 2026.
Why it mattersEMA engagement planned by IAMPS means biotech R&D and regulators must prioritize organ-on-chip validation pathways.